LLY - ELI LILLY & Co
1008.39
18.060 1.791%
Share volume: 2,796,955
Last Updated: 03-09-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.20%
PREVIOUS CLOSE
CHG
CHG%
$990.33
18.06
0.02%
Fundamental analysis
59%
Profitability
75%
Dept financing
22%
Liquidity
37%
Performance
57%
Performance
5 Days
2.56%
1 Month
-1.62%
3 Months
1.48%
6 Months
33.63%
1 Year
21.53%
2 Year
37.31%
Key data
Stock price
$1,008.39
DAY RANGE
$980.58 - $1,008.93
52 WEEK RANGE
$623.78 - $1,133.95
52 WEEK CHANGE
$22.37
DIVIDEND
$1.73
EX-DIVIDEND DATE
02-13-2026
NEXT EARNINGS DATE
08-07-2025
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972
Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news